Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 411 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Gastric Carcinoma Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastric Cancer
Interventions
capecitabine, oxaliplatin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, carboplatin, epirubicin hydrochloride, microarray analysis, polymorphism analysis, pharmacological study
Drug · Genetic · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab, Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
New Haven, Connecticut • Skokie, Illinois • Kansas City, Kansas + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Cancer, Melanoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer
Interventions
VE800, Nivolumab, Vancomycin Oral Capsule
Biological · Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
fluorouracil, leucovorin calcium, triacetyluridine
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
97
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Colorectal Neoplasms, Gastrointestinal Neoplasms
Interventions
JNJ-89402638, Bevacizumab, FOLFOX, FOLFIRI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Sarasota, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 11:10 PM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Gastric Cancer, GastroEsophageal Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
MDASI-GI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Cerritos, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer
Interventions
AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
38
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 21, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
Interventions
Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Irvine, California • Palo Alto, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 21, 2026, 11:10 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions
Pembrolizumab, Sonidegib
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 21, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Cancer
Interventions
CPI-613
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions
PF-08634404, Chemotherapy, Nivolumab
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
56
States / cities
Aurora, Colorado • Boulder, Colorado • Centennial, Colorado + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 11:10 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
Interventions
[18F]FAPI-74 PET/CT
Drug
Lead sponsor
SOFIE
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Cerritos, California • Irvine, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 11:10 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced May 21, 2026, 11:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Unresectable Metastatic Colo-rectal Cancer
Interventions
Chemoembolization with irinotecan Bead, Irinotecan
Procedure · Drug
Lead sponsor
Generic Devices Consulting, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Islet Cell Adenoma, Neoplasm Metastasis, Zollinger Ellison Syndrome
Interventions
combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1978 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Regorafenib, 5-Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced May 21, 2026, 11:10 PM EDT